$104 Million

Spruce Biosciences

Initial Public Offering

Lead Left Bookrunner, October 2020

Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia, or CAH. Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. In a 12-week Phase 2a proof-of-concept clinical trial, tildacerfont-treated patients suffering from classic CAH who had poor disease control despite being on standard of care therapy achieved approximately 80% reductions in hormones that are key drivers of disease. Furthermore, 174 subjects across six clinical trials to date have been administered tildacerfont with no serious adverse events, or SAEs, reported with tildacerfont treatment.

More Like This

Oct 2020
$219 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Oct 2020
$232 Million

Initial Public Offering

Bookrunner

View Details
Oct 2020
$288 Million

Initial Public Offering

Bookrunner

View Details